Additional Articles by the Authors
Michael C. Runken, PharmD; Joshua M. Noone, PhD; Christopher M. Blanchette, PhD, MBA;
Emily Zacherle, MS; Reuben Howden, PhD
Shared Decision-Making and Payer Preferences: IVIG or SCIG Route of Administration?
Gary M. Owens, MD
Jordan S. Orange, MD, PhD; Matt Johnson, BA; Barb Lennert, RN, BSN, MAOM; Katarzyna Shields,
PharmD, MBA, BCOP, BCPS; Michael Eaddy, PharmD, PhD
A Useful Tool for Evaluating Disease Severity and Alternative Treatments Efficacy
Gary Branning, MBA
Todd Williamson, MsC; Rajesh Kamalakar, MS; Augustina Ogbonnaya, MPH; Erin A. Zagadailov, PharmD,
MS; Michael Eaddy, PharmD, PhD; Charlie Kreilick, MBA
Important Insights from Real-World Treatment Patterns and Outcomes for Varicose Veins Management
Generic Imatinib: Can It Provide Significant Cost Relief for Patients?
Out-of-Pocket Cost of Therapy Can Affect Patients’ Excessive Sleepiness and Daytime Functioning
We Need More Research on True Value-Based Benefit Design that Will Improve Outcomes and Control Costs
Benefit Management Considerations for BPH Medications: Single Agent or Combination Therapy?
Results 1 - 9 of 9